Open AccessS145 Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection
Author(s) -
Jessica R. Allegretti,
Colleen Kelly,
Thomas Louie,
Monika Fisher,
Susy Hota,
Bharat Misra,
Nicholas W. Van Hise,
Eugene F. Yen,
Facg,
Jeff S. Bullock,
John Pullman,
Richard Nathan,
Michael Silverman,
Ian Davis,
Sarah McGill,
Sahil Khanna,
Darrell S. Pardi,
Robert Orenstein,
Ari Grinspan,
Najwa El-Nachef,
Colleen S. Kraft,
Shrish Budree,
Thomas J. Borody,
Zain Kassam
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000773052.38150.f9
Subject(s) - medicine , placebo , clinical endpoint , randomized controlled trial , clinical trial , dosing , adverse effect , guideline , alternative medicine , pathology